



20E
LP

EXPRESS MAIL NO.: EL 501 759 255 US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Schneider and Klein

Confirmation No.: 1985

Application No.: 09/096,589

Group Art Unit: 1652

Filed: June 12, 1998

Examiner: R. Prouty

For: INHIBITION OF THE SRC KINASE FAMILY
PATHWAY AS A METHOD OF TREATING
HBV INFECTION AND HEPATOCELLULAR
CARCINOMA

Attorney Docket No.: 5914-065-999

RECEIVED

APR 28 2003

AMENDMENT UNDER 37 C.F.R. § 1.111

TECH CENTER 1600/2900

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

In response to the Office Action mailed October 22, 2002, please enter the following amendments and consider the remarks made below in connection with the above-identified application. Also submitted herewith are: (a) a Petition for Extension of Time with the required fee; (b) a marked-up version of the claims amended herein as Appendix A; (c) a copy of the claims as pending in the present application after entry of the present amendment as Appendix B; (d) Fuortes et al., 1999, *J. Clin. Invest.* 104:327-35 as Exhibit 1; (e) Bouchard et al., 2001, *Science* 294:2376-8 as Exhibit 2; (f) Ohmori et al., 1999, *Thrombosis Res.* 93:291-8 as Exhibit 3; and (g) Graves et al., 1997, *J. Biol. Chem.* 272:1920-8 as Exhibit 4.

IN THE CLAIMS

Please amend claims 47-50 and add new claims 51-54 as follows:

47. (amended) A method for inhibiting Hepatitis B virus (HBV) infection or replication comprising administering a compound to an HBV-infected patient that inhibits Src kinase activity that is enhanced relative to a patient not infected with HBV, wherein said compound is a small organic molecule or decreases the activity of a non-virally encoded cellular protein.